NGS for Drugs, Patients and Clinical Trials Conference

Next-Generation Sequencing (NGS), along with a shift toward personalized medicine, is poised to revolutionize the drug discovery paradigm by offering unprecedented interrogation of the human genome at high resolution, and relatively low costs. While the widespread implementation of NGS is apparent, issues specific to drug development present new challenges for developers, including discerning actionable genomic information for novel targets, markers and utilization in clinical trials; developing informatics infrastructure and pipelines to deal with the computational complexity of NGS data; and navigating regulatory hurdles of informed consent and data sharing.  Cambridge Healthtech Institute is proud to announce the Inaugural NGS for Drugs, Patients and Clinical Trials, designed with drug developers in mind, to explore the unparalleled advantages of NGS technologies for translational research, while addressing common challenges.

Day 1: 

NGS for Decision Making during Drug Development and Clinical Trials

• Profiling and NGS in Cancer: Challenges and Applications to Targets, Models, and Resistance
• Impact of Next-Generation Sequencing on Oncology Drug Discovery and Early Clinical Development
• Devising Methods for Intuitively Handling Huge Data Sets to Simplify Biomarker Discovery
• Stratification of Clinical Trial Subjects Using Biomarkers Developed by Next-Generation Sequencing
• From Theory to Practice: Our First Thousand Samples

Day 2: 

Harnessing NGS Technologies for Identification of Causal Variants and "Driver" Mechanisms in Disease

• Case Study: Approaches and Challenges to Identifying Rare Somatic Mutations in Patients with CRC or NSCLC Using Targeted Deep Sequencing
• Deep Resequencing Identifies Tool Variants to Better Inform Drug Discovery and Assess Genetic Effect on Drug Response
• The Genetic Landscape of Hepatocellular Carcinoma
• Panel Discussion: Challenges, Opportunities and Outlook of NGS Technologies in Oncology Drug Development

Dissecting NGS Data for Actionable information

• Searching for Rare Molecular Markers Using Next-Generation Sequencing
• Enabling Oncology Drug Discovery by Integrative Omics
• Large-Scale Whole Genome Sequencing Data Analysis in Cloud: Evaluating the Association between RA Patients SNP and Their Response to SIMPONI® (Golimumab)

Integrating NGS Technologies into Biologics Development

• Molecular Characterization of Biotherapeutics by Next-Generation Sequencing
• Applications of NGS Technologies in the Discovery of microRNA Based Therapeutics